Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
OMICS Revolution for Precision Medicine
share announcement

OMICS Revolution for Precision Medicine

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Omics/Informatics".

Deadline for manuscript submissions: closed (20 May 2024) | Viewed by 12049

Special Issue Editor

Prof. Dr. Salvatore Scacco

E-Mail Website
Guest Editor
Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari “Aldo Moro”, 70124 Bari, Italy
Interests: translational research; personalized medicine; clinical biochemistry; molecular clinical biology; nanomedicine; regenerative medicine; neurosciences
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

A great challenge regarding research data in healthcare, bioinformatics, and precision medicine is the extraction of insightful, actionable knowledge from the streams of omics data related to patients that can be translated into effective therapies tailored to the molecular characteristics of the actual, biological state of an individual. In the context of host-related, genetic background vulnerabilities, or dysregulation of commensal microbiome promoting pathogenic infections, the role of comorbidities may now be examined through the manifold exploitation of diverse sequencing technologies.

Advances in “omics” technologies (e.g., genome, transcriptome, proteome, epigenome, metabolome) and their correlation with the clinical phenotypes of the individual patient are enabling medicine to move from a “one-size-fits-all” approach toward a “personalized” model, helping to clarify the molecular mechanisms underlying human disease and to provide both potential biomarkers and pharmacological targets for a more detailed patient stratification and personalized treatments. In this Special Issue, the most significant contributions of omics technologies, highlighting how these approaches are revealing diagnostic, prognostic, and therapeutic targets for future personalized interventions, are warmly welcome.

We especially encourage the submission of interdisciplinary works and multi-country collaborative research. We welcome the submission of original research papers using different study designs and critical and relevant reviews, including systematic reviews and meta-analyses, methodological papers, and manuscripts that emphasize theoretical content.

Prof. Dr. Salvatore Scacco
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision medicine and omics/bioinformatics 
  • health promotion 
  • translational research 
  • medicine and dentistry 
  • clinical biochemistry and clinical molecular biology 
  • biomedical research 
  • cancer research 
  • regenerative medicine 
  • nanomedicine 
  • oxidative stress 
  • personalized medicine 
  • natural compounds

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

12 pages, 557 KiB  
Article
Risk of Rhabdomyolysis Associated with Dexmedetomidine Use over the Past 10 Years: Insights from the EudraVigilance Database
by Nunzia Balzano, Annamaria Mascolo, Raffaella Di Napoli, Federica Colapietra, Marina Di Domenico, Annalisa Capuano and Francesca Gargano
J. Pers. Med. 2024, 14(9), 961; https://doi.org/10.3390/jpm14090961 - 10 Sep 2024
Viewed by 654
Abstract
Dexmedetomidine, a selective α2-adrenergic agonist, is favoured in intensive care for its minimal respiratory depression. This study evaluated the reporting frequency of rhabdomyolysis with dexmedetomidine compared to midazolam and propofol using the European pharmacovigilance database Eudravigilance. We conducted an observational, retrospective analysis of [...] Read more.
Dexmedetomidine, a selective α2-adrenergic agonist, is favoured in intensive care for its minimal respiratory depression. This study evaluated the reporting frequency of rhabdomyolysis with dexmedetomidine compared to midazolam and propofol using the European pharmacovigilance database Eudravigilance. We conducted an observational, retrospective analysis of Individual Case Safety Reports (ICSRs) from 1 January 2013, to 31 December 2023. Primary and secondary outcomes included the reporting frequencies of rhabdomyolysis and its indicative signs and symptoms, respectively. We retrieved 19,268 ICSRs, of which 364 reported rhabdomyolysis associated with dexmedetomidine (3.8%), midazolam (10.2%), propofol (76.9%), or combinations thereof (9.1%). Dexmedetomidine showed a significantly lower reporting frequency of rhabdomyolysis compared to propofol (ROR, 0.32; 95% CI, 0.19–0.55) but no significant difference compared to midazolam. Subgroup analyses revealed higher frequencies in males, especially with propofol. Despite limitations such as underreporting, our findings suggest dexmedetomidine poses a lower rhabdomyolysis risk than propofol, supporting its safe use for sedation in high-risk patients. It is important to note that due to the retrospective design of this study our findings are indicative of correlations rather than causation. Continuous monitoring and further studies are recommended to validate these results. Full article
(This article belongs to the Special Issue OMICS Revolution for Precision Medicine)
►▼ Show Figures

Figure 1

17 pages, 2648 KiB  
Article
Monitoring of Immune Memory by Phenotypical Lymphocyte Subsets Identikit: An Observational Study in a Blood Donors’ Cohort
by Marina Di Domenico, Enrica Serretiello, Annafrancesca Smimmo, Fábio França Vieira e Silva, Sonia Anna Raimondi, Caterina Pascariello, Maria Michela Marino, Lorenzo Lo Muzio, Vito Carlo Alberto Caponio, Stefania Cantore and Andrea Ballini
J. Pers. Med. 2024, 14(7), 733; https://doi.org/10.3390/jpm14070733 - 7 Jul 2024
Viewed by 854
Abstract
The cross-talk between the innate and adaptive immune response represents the first defense weapon against the threat of pathogens. Substantial evidence has shown a relationship between immune phenotype lymphocytes and COVID-19 disease severity and/or implication in susceptibility to SARS-CoV-2 infection. Recently, belonging to [...] Read more.
The cross-talk between the innate and adaptive immune response represents the first defense weapon against the threat of pathogens. Substantial evidence has shown a relationship between immune phenotype lymphocytes and COVID-19 disease severity and/or implication in susceptibility to SARS-CoV-2 infection. Recently, belonging to ABO blood groups has been investigated as a correlation factor to COVID-19 disease. This pilot study investigated lymphocyte typing in a cohort of blood donors to understand the underlying mechanism in SARS-CoV-2 infection linked to the blood group. The study cohort consisted of 20–64-year-old subjects, without comorbidities, from both sexes, who were COVID-19 vaccinated with previous or no infection history. Whole blood samples, collected at A.O.R.N. Sant’Anna and San Sebastiano Hospital (Campania Region), were processed by multiparametric cytofluorimetric assay, to characterize CD4+ helper and CD8+ cytotoxic T cell CD3+ subpopulations. The CD45RA, CCR7, CD27, CD28, CD57 and PD-1 markers were investigated to delineate the peripheral T-cell maturation stages. Differences were detected in ABO blood types in CD3+, CD4+ gated on CD3+, CD8+ and CD8+ gated on CD3+ percentage. These results contribute to identifying a memory cell “identikit” profile in COVID-19 disease, thus leading to a useful tool in precision medicine. Full article
(This article belongs to the Special Issue OMICS Revolution for Precision Medicine)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

14 pages, 2048 KiB  
Review
“GONE WITH THE WIND”: The Transitory Effects of COVID-19 on the Gynecological System
by Miriam Dellino, Antonella Vimercati, Antonio D’Amato, Gianluca Raffaello Damiani, Antonio Simone Laganà, Ettore Cicinelli, Vincenzo Pinto, Antonio Malvasi, Salvatore Scacco, Andrea Ballini, Leonardo Resta, Giuseppe Ingravallo, Eugenio Maiorano, Gerardo Cazzato and Eliano Cascardi
J. Pers. Med. 2023, 13(2), 312; https://doi.org/10.3390/jpm13020312 - 10 Feb 2023
Cited by 11 | Viewed by 5458
Abstract
The coronavirus disease no longer seems to represent an insurmountable global problem. This is thanks to the advent of coronavirus vaccines, which have alleviated the most serious symptoms associated with this disease. On the other hand, there are still many extrapulmonary symptoms of [...] Read more.
The coronavirus disease no longer seems to represent an insurmountable global problem. This is thanks to the advent of coronavirus vaccines, which have alleviated the most serious symptoms associated with this disease. On the other hand, there are still many extrapulmonary symptoms of COVID-19, and among these also those of a gynecological nature. At the moment, there are several questions in this field, one above all concerns the causal link between COVID-19, vaccines and gynecological alterations. Furthermore, another important aspect is represented by the clinical impact of post-COVID-19 gynecological alterations on the female population which, to date, would seem to be mainly due to their duration, even if the extent of these symptoms is still poorly understood. Furthermore, it is not possible to foresee eventual long-term aggravations, or more serious symptoms caused by other viral variants that may arrive in the future. In this review, we focus on this theme and attempt to reorganize the different pieces of a puzzle which, to date, does not seem to have shown us its complete picture. Full article
(This article belongs to the Special Issue OMICS Revolution for Precision Medicine)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research, Review

12 pages, 1882 KiB  
Systematic Review
Is the Non-Coding RNA miR-195 a Biodynamic Marker in the Pathogenesis of Head and Neck Squamous Cell Carcinoma? A Prognostic Meta-Analysis
by Mario Dioguardi, Francesca Spirito, Giorgia Apollonia Caloro, Lorenzo Lo Muzio, Stefania Cantore, Andrea Ballini, Salvatore Scacco, Annarita Malcangi, Salvatore Sembronio, Eliano Cascardi, Roberto Arrigoni, Michele Di Cosola and Riccardo Nocini
J. Pers. Med. 2023, 13(2), 275; https://doi.org/10.3390/jpm13020275 - 31 Jan 2023
Cited by 9 | Viewed by 1838
Abstract
Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of neoplasms whose histological derivation comes from the mucous membranes lining the epithelium: the oral cavity, the larynx, the hypopharynx, the nasopharynx, and the oropharynx. The etiopathogenetic mechanisms involving tumor genesis including [...] Read more.
Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of neoplasms whose histological derivation comes from the mucous membranes lining the epithelium: the oral cavity, the larynx, the hypopharynx, the nasopharynx, and the oropharynx. The etiopathogenetic mechanisms involving tumor genesis including the alteration of cell proliferation, apoptosis, invasion, migration, and death may involve alterations in the expression of microRNA (miR). To date there have been no systematic reviews with meta-analysis conducted specifically on the role of miR-195 in HNSCC; therefore, our hypothesis was to evaluate if the aberrant expression of miR-195 in HNSCC tissues may represent a prognostic biomarker of survival through the hazard ratio (HR) and relative risk (RR) analysis. The systematic review was designed according to the PRISMA indications; in total, three electronic databases were consulted (PubMed, Scopus, Cochrane Central Trial) including Google Scholar and the gray literature, and a combination of keywords was used such as miR-195 AND HNSCC, microRNA AND HNSCC and miR-195. The meta-analysis and trial sequential analysis were performed using RevMan 5.41 software and TSA software (Cochrane Collaboration, Copenhagen, Denmark). This search identified 1592 articles and, at the end of the selection process, three articles were included. The results of the meta-analysis reported an aggregated risk ratio for overall survival (OS) between the expression of miR-195 at the highest and lowest of 0.36 and 6, respectively, 95% CI: [0.25, 0.51]. Heterogeneity was evaluated through Chi2 = 0.05 df = 2 (p = 0.98) and the Higgins index I2 = 0%. The test for the overall effect was Z = 5.77 (p < 0.00001). The forest plot was in favor of higher OS in patients with high miR-195 expression. Full article
(This article belongs to the Special Issue OMICS Revolution for Precision Medicine)
►▼ Show Figures

Graphical abstract

11 pages, 887 KiB  
Systematic Review
Blood Biomarkers and Metabolomic Profiling for the Early Diagnosis of Vancomycin-Associated Acute Kidney Injury: A Systematic Review and Meta-Analysis of Experimental Studies
by Eleni Laou, Theodoros Mavridis, Nikolaos Papagiannakis, Gwendolyn Pais, Alberto Chighine, Jack Chang, Emanuela Locci, Ernesto D’Aloja, Marc Scheetz, Athanasios Chalkias and Theodoros Xanthos
J. Pers. Med. 2022, 12(9), 1397; https://doi.org/10.3390/jpm12091397 - 28 Aug 2022
Cited by 3 | Viewed by 2331
Abstract
Background: several blood-based biomarkers have been proposed for predicting vancomycin-associated kidney injury (VIKI). However, no systematic analysis has compared their prognostic value. Objective: this systematic review and meta-analysis was designed to investigate the role of blood biomarkers and metabolomic profiling as diagnostic and [...] Read more.
Background: several blood-based biomarkers have been proposed for predicting vancomycin-associated kidney injury (VIKI). However, no systematic analysis has compared their prognostic value. Objective: this systematic review and meta-analysis was designed to investigate the role of blood biomarkers and metabolomic profiling as diagnostic and prognostic predictors in pre-clinical studies of VIKI. Methods: a systematic search of PubMed was conducted for relevant articles from January 2000 to May 2022. Animal studies that administered vancomycin and studied VIKI were eligible for inclusion. Clinical studies, reviews, and non-English literature were excluded. The primary outcome was to investigate the relationship between the extent of VIKI as measured by blood biomarkers and metabolomic profiling. Risk of bias was assessed with the CAMARADES checklist the SYRCLE’s risk of bias tool. Standard meta-analysis methods (random-effects models) were used. Results: there were four studies for the same species, dosage, duration of vancomycin administration and measurement only for serum creatine and blood urea nitrogen in rats. A statistically significant increase was observed between serum creatinine in the vancomycin group compared to controls (pooled p = 0.037; Standardized Mean Difference: 2.93; 95% CI: 0.17 to 5.69; I2 = 92.11%). Serum BUN levels were not significantly different between control and vancomycin groups (pooled p = 0.11; SMD: 3.05; 95% CI: 0.69 to 6.8; I2 = 94.84%). We did not identify experimental studies using metabolomic analyses in animals with VIKI. Conclusions: a total of four studies in rodents only described outcomes of kidney injury as defined by blood biomarkers. Blood biomarkers represented included serum creatinine and BUN. Novel blood biomarkers have not been explored. Full article
(This article belongs to the Special Issue OMICS Revolution for Precision Medicine)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop